Eisai Co. Ltd. and Biogen Inc. should continue with their Phase III trial of elenbecestat in early Alzheimer’s disease, according to the data safety and monitoring board for the program. The DSMB recommendation came after a review of safety data, including the potential for decline in cognition.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?